The safety, tolerability, pharmacokinetics, and pharmacodynamics of nebulized pegylated interferon α-2b in healthy adults: a randomized phase 1 trial
Abstract Background Interferons (IFNs) are proteins that combat viruses and regulate the immune system. Studies have demonstrated that aerosol inhalation of IFNα is both effective and safe for treating respiratory infections. However, IFNα has a short half-life and is rapidly cleared by lung defense...
Saved in:
| Main Authors: | Wenqi Huang, Yanneng Kang, Yajun Zhao, Jiao Yang, Changjuan Dai, Weibing Wu, Jinchao Xu, Wen Jin, Xiaolu Wu, Qing Zhou |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-05-01
|
| Series: | BMC Pharmacology and Toxicology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40360-025-00937-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Recurrence risk factors for chronic hepatitis B virus-infected patients who achieve functional cure with pegylated interferon-α-2b-based therapy: a multicenter pilot study
by: Li-Jun Chang, et al.
Published: (2025-05-01) -
Successful treatment of hairy cell leukaemia with pegylated interferon-alpha-2A
by: Kata Ferenczi, et al.
Published: (2025-05-01) -
Is Combined Bulevirtide and Pegylated Interferon Therapy for Chronic Hepatitis D Superior over Bulevirtide Monotherapy?
by: V. E. Syutkin, et al.
Published: (2020-09-01) -
Success of early antiviral monotherapy with pegylated interferon α-2a for posttransplantation fibrosing cholestatic hepatitis C (a clinical case)
by: A. V. Chzhao, et al.
Published: (2018-08-01) -
Adding pegylated interferon-α to nucleos(t)ide analogs improves HBsAg clearance in chronic hepatitis B with low-level viremia
by: Lilin Wang, et al.
Published: (2025-08-01)